Medically reviewed by Kovalenko Svetlana Olegovna, PharmD. Last updated on 2020-03-17
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Inside, during meals, 2 times a day. The capsule should be swallowed completely, without violating its integrity.
The initial dose for adults is 1.5 mg per dose. With good tolerability (not earlier than 2 weeks), the dose can be increased to 3 mg and then-to 4.5-6 mg 2 times a day.
The maintenance dose is 3-6 mg 2 times a day.
The maximum daily dose is 12 mg.
If the drug was interrupted for several days, you should resume treatment with an initial dose of 1.5 mg 2 times a day, gradually increasing the dose.
In patients with impaired renal and hepatic function, dose adjustment is not required.
Solution for oral administration
Inside, during meals, 2 times a day during breakfast and dinner.
Dose selection. The initial dose is 1.5 mg (0.75 ml of solution) 2 times a day. When using the drug Alzenorm in patients who are particularly sensitive to the effects of cholinergic drugs, treatment should begin with a dose of 1 mg (0.5 ml of solution) 2 times a day.
With good tolerability (no earlier than 2 weeks), the dose can be increased to 3 mg (1.5 ml of solution). In case of good tolerability, it is possible to further increase the dose to 4.5 mg (2.25 ml of solution) 2 times a day and then to 6 mg (3 ml of solution) 2 times a day with a time interval of at least 2 weeks after each dose increase.
Adverse events, such as nausea, vomiting, abdominal pain, decreased appetite or weight loss, observed during treatment, may decrease after skipping one or more doses. If adverse effects persist, the daily dose of ALINORM should be reduced to the dose which the patient was well tolerated.
Maintenance dose - from 1.5 mg (0.75 ml of solution) to 6 mg (3 ml of solution) 2 times a day. In order to achieve a good clinical effect, the dose should be maintained at the maximum well-tolerated level.
The maximum daily dose is 12 mg (6 mg 2 times a day).
If the administration of the drug Alzenorm was interrupted for several days to reduce the risk of adverse events, you should resume treatment with an initial dose of 1.5 mg (0.75 ml of solution) 2 times a day, gradually increasing the dose.
In patients with impaired renal and/or hepatic function, dose adjustment is not required.
Method of dosing the solution for oral administration. The required amount of solution should be removed from the bottle using the supplied dispenser. The solution can be taken directly from the dispenser.
- Cholinesterase inhibitor [m -, n-Cholinomimetics, including anticholinesterase agents]
At a temperature not exceeding 30 °C.
Keep out of reach of children.The shelf life of the drug ALINORM
solution for oral administration 2 mg / ml — 3 years. After opening the bottle — 1 month.
capsules 1.5 mg — 3 years.
capsules of 3 mg — 3 years.
capsules 4.5 mg — 3 years.
capsules of 6 mg — 3 years.
Do not use after the expiration date indicated on the package.
|of rivastigmine tartrate||2.4 mg|
|(equivalent to 1.5, 3, 4.5 and 6 mg of rivastigmine, respectively)|
|excipients: MCC— 57,18/114,36/171,54/228,72 mg, colloidal silicon dioxide— 0,12/0,24/0,36/0,48 mg, magnesium stearate— 0,3/0,6/0,9/1,2 mg|
|solid gelatin capsule (lid): gelatin— 14,857/18,689/30,056/37,965 mg, titanium dioxide (E171) — 0,203/0,384/0,243/0,307 mg, dye "Sunny sunset" yellow— 0,001/0,127/0,055/0,07 mg, quinoline yellow dye— 0,14/−/−/− mg, azorubin dye— −/−/0,046/0,058 mg|
|solid gelatin capsule (body): gelatin— 22,285/28,034/45,084/56,068 mg, titanium dioxide (E171) — 0,304/0,576/0,365/1,152 mg, dye "Sunny sunset" yellow— 0,001/0,19/0,083/0,38 mg, quinoline yellow dye— 0,21/−/−/− mg, azorubin dye— −/−/0,068/− mg|
|red ink (for capsules of 1.5, 3 and 6 mg): shellac, propylene glycol, concentrated ammonia solution, dye iron oxide red (E172), potassium hydroxide, ethanol, isopropanol, butanol, water|
|white ink (for 4.5 mg capsules): shellac, propylene glycol, titanium dioxide (E171), sodium hydroxide, ethanol, isopropanol, butanol, povidone|
|Solution for oral administration||1 ml|
|of rivastigmine tartrate||3.2 mg|
|(equivalent to 2 mg of rivastigmine)|
|excipients: sodium benzoate-1 mg, sodium citrate-7.1 mg, citric acid-6.9 mg, dye yellow 06 098 (quinoline yellow (E104) - 28%, dextrose-60%, sodium sulfate-11.7%, silicon dioxide-0.3%) - 0.02 mg, water-up to 1 ml|
Capsules, 1.5 mg, 3 mg, 4.5 mg, 6 mg. 14 caps each in a PVC/aluminum foil blister. 2, 4 or 8 blisters in a cardboard pack.
Oral solution, 2 mg / ml. 120 ml of the solution in a bottle of dark glass, closed with a polypropylene lid with control of the first opening and a system against opening by children. 1 fl. together with a syringe for dosing and a stopper for sampling in a cardboard pack.
According to the recipe.
- F00 Dementia in Alzheimer's disease (G30 )
- F02. 3 Dementia in Parkinson's disease (G20 )